<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Mixed Connective Tissue Disease - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    

    
    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Mixed Connective Tissue Disease</span>
        </nav>

        <header class="page-header">
            <h1>Mixed Connective Tissue Disease</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Autoimmune</span>
                
                
                <span class="badge badge-mondo">
                    <a href="https://monarchinitiative.org/disease/MONDO:0005854" target="_blank">
                        MONDO:0005854
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Autoimmune Disease</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Connective Tissue Disease</span>
                
            </div>
        </header>

        <!-- Stats bar -->
        <div class="stats-bar">
            <div class="stat-item">
                <div class="stat-value">5</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">1</div>
                <div class="stat-label">Genes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Subtypes</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
        </div>

        <!-- Subtypes -->
        

        <!-- Pathophysiology -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">5</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Anti-U1 RNP Autoimmunity</div>
                
                <div class="item-desc">High-titer antibodies against U1 small nuclear ribonucleoprotein (U1 RNP) are the serological hallmark. These antibodies may directly contribute to disease through immune complex formation and cellular dysfunction.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Immunoglobulin Production</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31440254" target="_blank">PMID:31440254</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Mixed Connective Tissue Disease (MCTD) is a rare complex systemic autoimmune disease (SAD) characterized by the presence of increased levels of anti-U1 ribonucleoprotein autoantibodies and signs and symptoms that resemble other SADs such as systemic sclerosis (SSc), rheumatoid arthritis (RA),..."</div>
                
                
                <div class="evidence-explanation">This epigenome-wide study confirms anti-U1-RNP antibodies as the defining serological feature of MCTD, with pervasive hypomethylation at interferon-related genes (MX1, PARP9, DDX60, IFI44L) supporting the central role of this autoimmune response in disease pathogenesis.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">T Cell-Mediated Inflammation</div>
                
                <div class="item-desc">CD4+ T cells recognizing U1 RNP antigens drive the autoimmune response. Th1 and Th17 cytokines contribute to tissue inflammation and damage across multiple organ systems.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        CD4+ T Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000624" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Adaptive Immune Response</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/38479808" target="_blank">PMID:38479808</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Among the MCTD patients, patients with the SLE immunophenotype had higher proportions of Th1 cells"</div>
                
                
                <div class="evidence-explanation">Machine learning-based immunophenotyping revealed that MCTD patients with SLE-like features show significantly elevated Th1 cells (2.85% vs 1.33%, P=0.027) and plasmablasts, with enhanced interferon-alpha and interferon-gamma responses in central memory CD8+ T cells, demonstrating the central role of T cell-driven inflammation in disease heterogeneity.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Vascular Dysfunction</div>
                
                <div class="item-desc">Endothelial injury and proliferative vasculopathy similar to systemic sclerosis contribute to Raynaud&#39;s phenomenon and may lead to pulmonary arterial hypertension in some patients.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Endothelial Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000115" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Blood Vessel Development</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16084319" target="_blank">PMID:16084319</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"It is the cutaneous symptom of a systemic vasculopathy that is characterized by intimal fibrosis and blood vessel obliteration that frequently leads to visceral involvement, particularly pulmonary hypertension."</div>
                
                
                <div class="evidence-explanation">Raynaud phenomenon in MCTD reflects an underlying systemic vasculopathy with intimal fibrosis and vascular obliteration, providing the mechanistic link between endothelial dysfunction and pulmonary arterial hypertension development.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/37497727" target="_blank">PMID:37497727</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Pooled prevalence of PAH in MCTD patients was 12.53% [95% CI 8.30-18.48%]"</div>
                
                
                <div class="evidence-explanation">This systematic review and meta-analysis of 983 MCTD patients establishes pulmonary arterial hypertension as a significant vascular complication, occurring in approximately 12.5% of patients, with mortality rates reaching up to 81.8% in affected individuals.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Muscle Inflammation</div>
                
                <div class="item-desc">Inflammatory myopathy with lymphocytic infiltration of skeletal muscle leads to proximal muscle weakness, similar to polymyositis.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        Skeletal Muscle Cell
                        
                        <a href="https://www.ebi.ac.uk/ols4/ontologies/cl/classes/http%253A%252F%252Fpurl.obolibrary.org%252Fobo%252FCL_0000188" target="_blank" style="color: inherit; margin-left: 4px;">‚Üó</a>
                        
                    </span>
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Inflammatory Response</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39876825" target="_blank">PMID:39876825</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"In biopsied muscle specimens, common findings were mild myogenic change, increased necrotic and regenerating fibers, and inflammatory infiltrates predominating in the perivascular region."</div>
                
                
                <div class="evidence-explanation">This 2025 case series of nine MCTD myositis patients demonstrates the characteristic inflammatory myopathy with perivascular lymphocytic infiltration, muscle fiber necrosis and regeneration, and atypical weakness patterns affecting proximal and axial muscles, reflecting the heterogeneity of MCTD-associated muscle involvement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Type I Interferon Signature</div>
                
                <div class="item-desc">Pervasive DNA hypomethylation at interferon-inducible genes drives constitutive type I interferon pathway activation. This epigenetic signature is shared with SLE and Sjogren syndrome but is particularly pronounced in MCTD, contributing to immune dysregulation and disease heterogeneity.</div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">Type I Interferon Signaling Pathway</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/31440254" target="_blank">PMID:31440254</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"We observed a pervasive hypomethylation involving 170 genes enriched for immune-related function such as those involved in type I interferon signaling pathways or in negative regulation of viral genome replication."</div>
                
                
                <div class="evidence-explanation">The first epigenome-wide association study in MCTD revealed widespread DNA hypomethylation at interferon-related genes (MX1, PARP9, DDX60, IFI44L) with evidence that genetic variants at IRF7 and IFI44 may exert disease risk through DNA methylation changes, establishing type I interferon pathway activation as a central molecular mechanism shared with SLE and Sjogren syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Causal Graph -->
        

        <!-- Phenotypes -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Raynaud Phenomenon
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Vascular</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0030880" target="_blank">
                            HP:0030880
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Present in most patients</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/16084319" target="_blank">PMID:16084319</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Raynaud&#39;s phenomenon affects most patients who have mixed connective tissue disease (MCTD) and frequently represents the initial manifestation of the disease."</div>
                
                
                <div class="evidence-explanation">Raynaud phenomenon is nearly universal in MCTD and often the presenting symptom, reflecting the underlying systemic vasculopathy characterized by intimal fibrosis and vascular obliteration that links this cutaneous manifestation to visceral complications including pulmonary hypertension.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Arthritis
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0001369" target="_blank">
                            HP:0001369
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Polyarthritis common</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/718271" target="_blank">PMID:718271</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Arthritis occurred in all 20 patients, being the presenting complaint in 11 patients."</div>
                
                
                <div class="evidence-explanation">This landmark 5-year longitudinal study demonstrated that arthritis is universal in MCTD, often as the presenting manifestation, with symmetric involvement of PIP, MCP, wrists, MTP joints and knees mimicking rheumatoid arthritis but with predominantly lymphocytic non-inflammatory effusions and good response to low-dose corticosteroids.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Myopathy
                    
                    <span class="phenotype-freq">FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Musculoskeletal</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0003198" target="_blank">
                            HP:0003198
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Inflammatory myositis</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="https://pubmed.ncbi.nlm.nih.gov/39876825" target="_blank">PMID:39876825</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                </div>
                
                <div class="evidence-snippet">"Eight patients had muscle weakness in the proximal extremities, and overall, six patients had atypical weakness in the face, neck, wrist, or fingers."</div>
                
                
                <div class="evidence-explanation">MCTD-associated myositis presents with both typical proximal muscle weakness and atypical distributions affecting axial and distal muscles, with muscle biopsy showing perivascular inflammatory infiltrates and muscle fiber necrosis, reflecting the heterogeneous nature of MCTD myopathy that may require intensive immunosuppressive therapy.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box phenotype-box">
                <div class="item-name">
                    Edema
                    
                    <span class="phenotype-freq">VERY_FREQUENT</span>
                    
                    
                    <span class="phenotype-category">Dermatological</span>
                    
                    
                    <span class="phenotype-id">
                        <a href="https://hpo.jax.org/browse/term/HP:0000969" target="_blank">
                            HP:0000969
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Puffy hands characteristic</div>
                
                
                
    
    
            </div>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    HLA-DR4
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Risk Factor)</span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    NSAIDs
                    
                </div>
                
                <div class="item-desc">For mild arthritis and myalgia.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Corticosteroids
                    
                </div>
                
                <div class="item-desc">For moderate to severe disease manifestations.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Methotrexate
                    
                </div>
                
                <div class="item-desc">Steroid-sparing agent for arthritis and myositis.</div>
                
                
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Hydroxychloroquine
                    
                </div>
                
                <div class="item-desc">For skin and joint manifestations.</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Anti-U1 RNP Antibodies
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Diagnostic hallmark, required for diagnosis</div>
                
                
    
    
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    ANA
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Elevated)</span>
                    
                </div>
                
                <div class="item-desc">Context: Typically high-titer speckled pattern</div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Mixed Connective Tissue Disease
category: Autoimmune
parents:
- Autoimmune Disease
- Connective Tissue Disease
disease_term:
  preferred_term: Mixed Connective Tissue Disease
  term:
    id: MONDO:0005854
    label: mixed connective tissue disease
description: &gt;-
  An autoimmune overlap syndrome characterized by features of systemic lupus
  erythematosus, systemic sclerosis, and polymyositis, with high titers of
  anti-U1 RNP antibodies. Patients typically present with Raynaud&#39;s phenomenon,
  swollen hands, arthritis, and myositis.
pathophysiology:
- name: Anti-U1 RNP Autoimmunity
  description: &gt;-
    High-titer antibodies against U1 small nuclear ribonucleoprotein (U1 RNP)
    are the serological hallmark. These antibodies may directly contribute to
    disease through immune complex formation and cellular dysfunction.
  biological_processes:
  - preferred_term: Immunoglobulin Production
    term:
      id: GO:0002377
      label: immunoglobulin production
  evidence:
  - reference: PMID:31440254
    supports: SUPPORT
    snippet: &#34;Mixed Connective Tissue Disease (MCTD) is a rare complex systemic autoimmune disease (SAD) characterized by the presence of increased levels of anti-U1 ribonucleoprotein autoantibodies and signs and symptoms that resemble other SADs such as systemic sclerosis (SSc), rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE).&#34;
    explanation: This epigenome-wide study confirms anti-U1-RNP antibodies as the defining serological feature of MCTD, with pervasive hypomethylation at interferon-related genes (MX1, PARP9, DDX60, IFI44L) supporting the central role of this autoimmune response in disease pathogenesis.
- name: T Cell-Mediated Inflammation
  description: &gt;-
    CD4+ T cells recognizing U1 RNP antigens drive the autoimmune response.
    Th1 and Th17 cytokines contribute to tissue inflammation and damage
    across multiple organ systems.
  cell_types:
  - preferred_term: CD4+ T Cell
    term:
      id: CL:0000624
      label: CD4-positive, alpha-beta T cell
  biological_processes:
  - preferred_term: Adaptive Immune Response
    term:
      id: GO:0002250
      label: adaptive immune response
  evidence:
  - reference: PMID:38479808
    supports: SUPPORT
    snippet: &#34;Among the MCTD patients, patients with the SLE immunophenotype had higher proportions of Th1 cells&#34;
    explanation: Machine learning-based immunophenotyping revealed that MCTD patients with SLE-like features show significantly elevated Th1 cells (2.85% vs 1.33%, P=0.027) and plasmablasts, with enhanced interferon-alpha and interferon-gamma responses in central memory CD8+ T cells, demonstrating the central role of T cell-driven inflammation in disease heterogeneity.
- name: Vascular Dysfunction
  description: &gt;-
    Endothelial injury and proliferative vasculopathy similar to systemic
    sclerosis contribute to Raynaud&#39;s phenomenon and may lead to pulmonary
    arterial hypertension in some patients.
  cell_types:
  - preferred_term: Endothelial Cell
    term:
      id: CL:0000115
      label: endothelial cell
  biological_processes:
  - preferred_term: Blood Vessel Development
    term:
      id: GO:0001568
      label: blood vessel development
  evidence:
  - reference: PMID:16084319
    supports: SUPPORT
    snippet: &#34;It is the cutaneous symptom of a systemic vasculopathy that is characterized by intimal fibrosis and blood vessel obliteration that frequently leads to visceral involvement, particularly pulmonary hypertension.&#34;
    explanation: Raynaud phenomenon in MCTD reflects an underlying systemic vasculopathy with intimal fibrosis and vascular obliteration, providing the mechanistic link between endothelial dysfunction and pulmonary arterial hypertension development.
  - reference: PMID:37497727
    supports: SUPPORT
    snippet: &#34;Pooled prevalence of PAH in MCTD patients was 12.53% [95% CI 8.30-18.48%]&#34;
    explanation: This systematic review and meta-analysis of 983 MCTD patients establishes pulmonary arterial hypertension as a significant vascular complication, occurring in approximately 12.5% of patients, with mortality rates reaching up to 81.8% in affected individuals.
- name: Muscle Inflammation
  description: &gt;-
    Inflammatory myopathy with lymphocytic infiltration of skeletal muscle
    leads to proximal muscle weakness, similar to polymyositis.
  cell_types:
  - preferred_term: Skeletal Muscle Cell
    term:
      id: CL:0000188
      label: cell of skeletal muscle
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:39876825
    supports: SUPPORT
    snippet: &#34;In biopsied muscle specimens, common findings were mild myogenic change, increased necrotic and regenerating fibers, and inflammatory infiltrates predominating in the perivascular region.&#34;
    explanation: This 2025 case series of nine MCTD myositis patients demonstrates the characteristic inflammatory myopathy with perivascular lymphocytic infiltration, muscle fiber necrosis and regeneration, and atypical weakness patterns affecting proximal and axial muscles, reflecting the heterogeneity of MCTD-associated muscle involvement.
- name: Type I Interferon Signature
  description: &gt;-
    Pervasive DNA hypomethylation at interferon-inducible genes drives constitutive
    type I interferon pathway activation. This epigenetic signature is shared with
    SLE and Sjogren syndrome but is particularly pronounced in MCTD, contributing
    to immune dysregulation and disease heterogeneity.
  biological_processes:
  - preferred_term: Type I Interferon Signaling Pathway
    term:
      id: GO:0060337
      label: type I interferon signaling pathway
  evidence:
  - reference: PMID:31440254
    supports: SUPPORT
    snippet: &#34;We observed a pervasive hypomethylation involving 170 genes enriched for immune-related function such as those involved in type I interferon signaling pathways or in negative regulation of viral genome replication.&#34;
    explanation: The first epigenome-wide association study in MCTD revealed widespread DNA hypomethylation at interferon-related genes (MX1, PARP9, DDX60, IFI44L) with evidence that genetic variants at IRF7 and IFI44 may exert disease risk through DNA methylation changes, establishing type I interferon pathway activation as a central molecular mechanism shared with SLE and Sjogren syndrome.
phenotypes:
- name: Raynaud Phenomenon
  category: Vascular
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Raynaud Phenomenon
    term:
      id: HP:0030880
      label: Raynaud phenomenon
  notes: Present in most patients
  evidence:
  - reference: PMID:16084319
    supports: SUPPORT
    snippet: &#34;Raynaud&#39;s phenomenon affects most patients who have mixed connective tissue disease (MCTD) and frequently represents the initial manifestation of the disease.&#34;
    explanation: Raynaud phenomenon is nearly universal in MCTD and often the presenting symptom, reflecting the underlying systemic vasculopathy characterized by intimal fibrosis and vascular obliteration that links this cutaneous manifestation to visceral complications including pulmonary hypertension.
- name: Arthritis
  category: Musculoskeletal
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Arthritis
    term:
      id: HP:0001369
      label: Arthritis
  notes: Polyarthritis common
  evidence:
  - reference: PMID:718271
    supports: SUPPORT
    snippet: &#34;Arthritis occurred in all 20 patients, being the presenting complaint in 11 patients.&#34;
    explanation: This landmark 5-year longitudinal study demonstrated that arthritis is universal in MCTD, often as the presenting manifestation, with symmetric involvement of PIP, MCP, wrists, MTP joints and knees mimicking rheumatoid arthritis but with predominantly lymphocytic non-inflammatory effusions and good response to low-dose corticosteroids.
- name: Myopathy
  category: Musculoskeletal
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  notes: Inflammatory myositis
  evidence:
  - reference: PMID:39876825
    supports: SUPPORT
    snippet: &#34;Eight patients had muscle weakness in the proximal extremities, and overall, six patients had atypical weakness in the face, neck, wrist, or fingers.&#34;
    explanation: MCTD-associated myositis presents with both typical proximal muscle weakness and atypical distributions affecting axial and distal muscles, with muscle biopsy showing perivascular inflammatory infiltrates and muscle fiber necrosis, reflecting the heterogeneous nature of MCTD myopathy that may require intensive immunosuppressive therapy.
- name: Edema
  category: Dermatological
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Edema
    term:
      id: HP:0000969
      label: Edema
  notes: Puffy hands characteristic
biochemical:
- name: Anti-U1 RNP Antibodies
  presence: Elevated
  context: Diagnostic hallmark, required for diagnosis
- name: ANA
  presence: Elevated
  context: Typically high-titer speckled pattern
genetic:
- name: HLA-DR4
  association: Risk Factor
treatments:
- name: NSAIDs
  description: For mild arthritis and myalgia.
- name: Corticosteroids
  description: For moderate to severe disease manifestations.
- name: Methotrexate
  description: Steroid-sparing agent for arthritis and myositis.
- name: Hydroxychloroquine
  description: For skin and joint manifestations.
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Mixed_Connective_Tissue_Disease.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
</body>
</html>